Abstract
Purpose of Review: The objective of this article is to highlight the potential role of the galantamine-memantine combination as a novel antioxidant treatment for schizophrenia. Recent Findings: In addition to the well-known mechanisms of action of galantamine and memantine, these medications also have antioxidant activity. Furthermore, an interplay exists between oxidative stress, inflammation (redox-inflammatory hypothesis), and kynurenine pathway metabolites. Also, there is an interaction between brain-derived neurotrophic factor and oxidative stress in schizophrenia. Oxidative stress may be associated with positive, cognitive, and negative symptoms and impairments in white matter integrity in schizophrenia. The antipsychotic-galantamine-memantine combination may provide a novel strategy in schizophrenia to treat positive, cognitive, and negative symptoms. Summary: A “single antioxidant” may be inadequate to counteract the complex cascade of oxidative stress. The galantamine-memantine combination as “double antioxidants” is promising. Hence, randomized controlled trials are warranted with the antipsychotic-galantamine-memantine combination with oxidative stress and antioxidant biomarkers in schizophrenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 37-50 |
| Number of pages | 14 |
| Journal | Current Behavioral Neuroscience Reports |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 15 2019 |
| Externally published | Yes |
Keywords
- Antioxidant
- Clinical high risk
- Galantamine
- Memantine
- Oxidative stress
- Schizophrenia
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Behavioral Neuroscience
